Abstract
Many lines of evidence indicate that connexin genes expressing gap junction (GJ) proteins inhibit tumor cell proliferation. However, the precise molecular mechanisms remain unclear. In this study, we show that overexpression of connexin43 (Cx43) suppressed proliferation of human osteosarcoma U2OS cells through inhibition of the cell cycle transition from G1 to S phase. This inhibition was attributed to a significant accumulation of the hypophosphorylated retinoblastoma (Rb) protein, which was causally related to decreases in the kinase activities of cyclin-dependent kinases (CDKs) 2 and 4. Enforced Cx43 expression markedly increased the level of the CDK inhibitor p27. This increase resulted from an increased synthesis and a reduced degradation of the p27 proteins, but not influence of the p27 mRNA. Moreover, we show that the Cx43-modulated GJ function was the main contributor to the elevation in p27 levels, in which cAMP was involved. These data suggest that Cx43 appears to inhibit proliferation of U2OS cells by increasing the levels of p27 proteins via post-transcriptional regulatory mechanisms.
Similar content being viewed by others
References
Bennett MVL, Barrio LC, Bargiello TA, Spray DC . 1991 Neuron 6: 305–320
Beyer EC, Paul DL, Goodenough DA . 1987 J. Cell Biol. 105: 2621–2629
Beyer EC . 1993 Int. Rev. Cytol. 137: 1–37
Boynton AL, Whitfield JF . 1983 Adv. Cycl. Nucl. Res. 15: 193–294
Bradshaw SL, Naus CCG, Zhu D, Kidder GM, Han VK . 1993 Growth Regul. 3: 26–29
Bruzzone R, White TW, Paul DL . 1996 Eur. J. Biochem. 238: 1–27
Chen SCD, Pelletier B, Ao P, Boynton AL . 1995 Cell Growth Differ. 6: 681–690
Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS . 1991 Proc. Natl. Acad. Sci. USA 89: 6028–6032
Duflot-Dancer A, Mesnil M, Yamasaki H . 1997 Oncogene 15: 2151–2158
Dyson N . 1998 Genes Dev. 12: 2245–2262
Fitzgerald DJ, Yamasaki H . 1990 Teratog. Carcinog. Mutagen 10: 89–102
Goodenough DA, Goliger JA, Paul DL . 1996 Annu. Rev. Biochem. 65: 475–502
Grossel MJ, Baker GL, Hinds PW . 1999 J. Biol. Chem. 274: 29960–29967
Huang RP, Fan Y, Hossain MZ, Peng A, Zeng ZL, Boynton AL . 1998 Cancer Res. 58: 5089–5096
Kandel ER . 2000 Brain Res. Rev. 32: 3–5
Kato J, Matsuoka M, Polyak K, Massague J, Sherr CJ . 1994 Cell 79: 487–496
Koffler L, Roshong S, Park IK, Cesen-Cummings K, Thompson DC, Dwyer-Nield LD, Rice P, Mamay C, Malkinson AM, Ruch RJ . 2000 J. Cell. Biochem. 79: 347–354
Krutovskikh VA, Troyanovsky SM, Piccoli C, Tsuda H, Asamoto M, Yamasaki H . 2000 Oncogene 19: 505–513
Kumar NM, Gilula NB . 1996 Cell 84: 381–388
Loewenstein WR . 1979 Biochim. Biophys. Acta Cancer Rev. 560: 1–5
Martin W, Zempel G, Hulser D, Willecke K . 1991 Cancer Res. 51: 5348–5354
Martyn KD, Kurata WE, Warn-Cramer BJ, Burt JM, TenBroek E, Lau AF . 1997 Cell. Growth Differ. 8: 1015–1027
Mehta PP, Bertram JS, Loewenstein WR . 1986 Cell 44: 187–196
Mehta PP, Rotz-Wagenblatt A, Rose B, Shalloway D, Loewenstein WR . 1991 J. Mem. Biol. 124: 207–225
Mehta PP, Lokeshwar BL, Schiller PC, Bendix MV, Ostenson RC, Howard GA, Roos BA . 1996 Mol. Carcinog. 15: 18–32
Mesnil M, Krutovskikh VA, Piccoli C, Elfgang C, Traub O, Willecke K, Yamasaki H . 1995 Cancer Res. 55: 629–639
Omori Y, Yamasaki H . 1998 Int. J. Cancer 78: 446–453
Orford K, Orford CC, Byers SW . 1999 J. Cell Biol. 146: 855–867
Paul DL . 1995 Cur. Opin. Cell. Biol. 7: 665–672
Proulx AA, Lin ZX, Naus CCG . 1997 Cell Growth Differ. 8: 533–540
Rae RS, Mehta PP, Chang CC, Trosko JE, Ruch RJ . 1998 Mol. Carcinog. 22: 120–127
Sherr CJ . 1996 Science 274: 1672–1677
Sherr CJ, Roberts JM . 1999 Genes Dev. 13: 1501–1512
Statuto M, Audebet C, Tonoli H, Selmi-Ruby S, Rousset B, Munari-Silem Y . 1997 J. Biol. Chem. 272: 24710–24716
Temme A, Buchmann A, Gabriel HD, Nelles E, Schwarz M, Willecke K . 1997 Curr. Biol. 7: 713–716
Trosko JE, Madhukar BV, Chang CC . 1993 Life Sci. 53: 1–19
Weinberg RA . 1995 Cell 81: 323–330
Yamasaki H, Mesnil M, Omori Y, Mironor N, Krutovskikh V . 1995 Mutat. Res. 333: 181–188
Yamasaki H, Naus CCG . 1996 Carcinogenesis (Lond.) 17: 1199–1213
Yamasaki H, Krutovskikh V, Mesnil M, Tanaka T, Zaidan-Dagli ML, Omori Y . 1999 C.R. Acad. Sci. III 322: 151–159
Zhang YW, Morita I, Nishida M, Murota S . 1999a J. Cell. Physiol. 180: 305–313
Zhang YW, Morita I, Yao XS, Murota S . 1999b Prostaglandins Leukotr. Essen. Fatty Acids 61: 33–40
Zhang YW, Morita I, Gang S, Yao XS, Murota S . 2000a Planta Med. 66: 114–118
Zhang YW, Morita I, Zhang L, Gang S, Yao XS, Murota S . 2000b Planta Med. 66: 119–123
Zhu D, Kidder GM, Caveney S, Naus CCG . 1992 Proc. Natl. Acad. Sci. USA 89: 10218–10221
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, YW., Morita, I., Ikeda, M. et al. Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene 20, 4138–4149 (2001). https://doi.org/10.1038/sj.onc.1204563
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204563
- Springer Nature Limited
Keywords
This article is cited by
-
MiRNA-related metastasis in oral cancer: moving and shaking
Cancer Cell International (2023)
-
Connexin 32 overexpression increases proliferation, reduces gap junctional intercellular communication, motility and epithelial-to-mesenchymal transition in Hs578T breast cancer cells
Journal of Cell Communication and Signaling (2022)
-
Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application
Journal of Biomedical Science (2019)
-
Connexin and pannexin channels in cancer
BMC Cell Biology (2016)
-
Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1
BMC Cancer (2015)